肿瘤相关性贫血（cancer related anemia,CRA）主要是指肿瘤患者在疾病的发展过程中及治疗过程中发生的贫血。近年随着人们生活水平的不断提高,人口老龄化的不断加剧,老年恶性肿瘤患者也在不断增多,老年恶性肿瘤患者所占比例较大[1],而...肿瘤相关性贫血（cancer related anemia,CRA）主要是指肿瘤患者在疾病的发展过程中及治疗过程中发生的贫血。近年随着人们生活水平的不断提高,人口老龄化的不断加剧,老年恶性肿瘤患者也在不断增多,老年恶性肿瘤患者所占比例较大[1],而贫血也随之成为老年恶性肿瘤患者常见的并发症之一,贫血不但对老年恶性肿瘤患者的生活质量有着非常大的影响,同时与老年恶性肿瘤疾病进展和复发密切相关，使肿瘤治疗决策难度、风险也大大的增加。展开更多
To induce the growth and differentiation of dendritic cells (DCs) from human cord blood, CD34 + cells isolated from human cord blood by mini MACS were cultured in a liquid culture system with rhSCF, rhGM CSF, rhTNF α...To induce the growth and differentiation of dendritic cells (DCs) from human cord blood, CD34 + cells isolated from human cord blood by mini MACS were cultured in a liquid culture system with rhSCF, rhGM CSF, rhTNF α and rhFL for 10 days. Then the induced cells were characterized by DC′s morphological and phenotypic properties. In addition, they stimulated the proliferation of allogeneic T cells and possessed an efficient capacity for initiating T cell dependent antitumor immune responses in vitro. It is concluded that mature DCs could be obtained from human cord blood CD34 + cells.展开更多
晚期尿路上皮癌严重影响患者生存。长期以来,以顺铂为基础的化疗方案作为晚期转移性尿路上皮癌的一线标准治疗方案,患者中位生存期仅8~14个月[1-3]。随着免疫时代的到来,多个程序性死亡-受体1(programmed cell death protein 1,PD-1)/...晚期尿路上皮癌严重影响患者生存。长期以来,以顺铂为基础的化疗方案作为晚期转移性尿路上皮癌的一线标准治疗方案,患者中位生存期仅8~14个月[1-3]。随着免疫时代的到来,多个程序性死亡-受体1(programmed cell death protein 1,PD-1)/程序性死亡-配体1(programmed cell death ligand 1,PD-L1)抑制剂被美国食品药品监督管理局(Food and Drug Administration,FDA)和国家药品监督管理局(National Medical Products Administration,NMPA)批准用于治疗晚期尿路上皮癌[4-6]。另外,成纤维生长因子受体(fibroblast growth factor receptor,FGFR)抑制剂与抗体偶联(antibody-drug conjugate,ADC)药物的研究取得突破,并先后被批准用于临床[7-11]。展开更多
文摘肿瘤相关性贫血（cancer related anemia,CRA）主要是指肿瘤患者在疾病的发展过程中及治疗过程中发生的贫血。近年随着人们生活水平的不断提高,人口老龄化的不断加剧,老年恶性肿瘤患者也在不断增多,老年恶性肿瘤患者所占比例较大[1],而贫血也随之成为老年恶性肿瘤患者常见的并发症之一,贫血不但对老年恶性肿瘤患者的生活质量有着非常大的影响,同时与老年恶性肿瘤疾病进展和复发密切相关，使肿瘤治疗决策难度、风险也大大的增加。
文摘To induce the growth and differentiation of dendritic cells (DCs) from human cord blood, CD34 + cells isolated from human cord blood by mini MACS were cultured in a liquid culture system with rhSCF, rhGM CSF, rhTNF α and rhFL for 10 days. Then the induced cells were characterized by DC′s morphological and phenotypic properties. In addition, they stimulated the proliferation of allogeneic T cells and possessed an efficient capacity for initiating T cell dependent antitumor immune responses in vitro. It is concluded that mature DCs could be obtained from human cord blood CD34 + cells.
文摘晚期尿路上皮癌严重影响患者生存。长期以来,以顺铂为基础的化疗方案作为晚期转移性尿路上皮癌的一线标准治疗方案,患者中位生存期仅8~14个月[1-3]。随着免疫时代的到来,多个程序性死亡-受体1(programmed cell death protein 1,PD-1)/程序性死亡-配体1(programmed cell death ligand 1,PD-L1)抑制剂被美国食品药品监督管理局(Food and Drug Administration,FDA)和国家药品监督管理局(National Medical Products Administration,NMPA)批准用于治疗晚期尿路上皮癌[4-6]。另外,成纤维生长因子受体(fibroblast growth factor receptor,FGFR)抑制剂与抗体偶联(antibody-drug conjugate,ADC)药物的研究取得突破,并先后被批准用于临床[7-11]。
